Fortress Biotech/$FBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fortress Biotech
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Ticker
$FBIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
101
ISIN
US34960Q3074
Website
Fortress Biotech Metrics
BasicAdvanced
$53M
-
-$2.20
1.77
-
Price and volume
Market cap
$53M
Beta
1.77
52-week high
$2.89
52-week low
$1.33
Average daily volume
225K
Financial strength
Current ratio
1.722
Quick ratio
1.489
Long term debt to equity
216.099
Total debt to equity
228.517
Interest coverage (TTM)
-6.46%
Profitability
EBITDA (TTM)
-84.282
Gross margin (TTM)
3.70%
Net profit margin (TTM)
-71.24%
Operating margin (TTM)
-153.58%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
-32.37%
Return on equity (TTM)
-746.25%
Valuation
Price to revenue (TTM)
0.72
Price to book
2.39
Price to tangible book (TTM)
-6.22
Price to free cash flow (TTM)
-0.455
Free cash flow yield (TTM)
-219.67%
Free cash flow per share (TTM)
-395.41%
Growth
Revenue change (TTM)
-32.11%
Earnings per share change (TTM)
-62.69%
3-year revenue growth (CAGR)
-10.69%
10-year revenue growth (CAGR)
60.80%
3-year earnings per share growth (CAGR)
-45.13%
10-year earnings per share growth (CAGR)
-14.21%
What the Analysts think about Fortress Biotech
Analyst ratings (Buy, Hold, Sell) for Fortress Biotech stock.
Fortress Biotech Financial Performance
Revenues and expenses
Fortress Biotech Earnings Performance
Company profitability
Fortress Biotech News
AllArticlesVideos
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
GlobeNewsWire·3 days ago
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
GlobeNewsWire·7 days ago
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fortress Biotech stock?
Fortress Biotech (FBIO) has a market cap of $53M as of June 27, 2025.
What is the P/E ratio for Fortress Biotech stock?
The price to earnings (P/E) ratio for Fortress Biotech (FBIO) stock is 0 as of June 27, 2025.
Does Fortress Biotech stock pay dividends?
No, Fortress Biotech (FBIO) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Fortress Biotech dividend payment date?
Fortress Biotech (FBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Fortress Biotech?
Fortress Biotech (FBIO) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.